Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Zylox-Tonbridge Medical Technology Co., Ltd.
歸創通橋醫療科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2190)

POLL RESULTS OF THE 2025 FIRST EXTRAORDINARY GENERAL MEETING HELD ON OCTOBER 24, 2025

Reference is made to the announcement (the "**Announcement**") of Zylox-Tonbridge Medical Technology Co., Ltd. (the "**Company**") and the circular of the Company (the "**Circular**") both dated October 8, 2025. Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement and the Circular.

The Board wishes to announce that the EGM was convened and held at Meeting Room 202, 2nd Floor, Zylox-Tonbridge Industrial Park, No. 270 Shuyun Road, Cangqian Street, Yuhang District, Hangzhou, Zhejiang, the PRC at 9:00 a.m. on Friday, October 24, 2025, and all the resolutions proposed at the EGM were duly passed.

As at the record date, for determining the entitlement of the Shareholders to attend and vote at the EGM (i.e. October 24, 2025) (the "**Record Date**"), the total number of issued Shares include 316,277,613 H Shares (excluding Treasury Shares held or deposited with CCASS) and 7,781,257 Domestic Shares, which were the total number of Shares of the Company entitling the Shareholders to attend and vote (save and except for the resolutions numbered 4, 5 and 6) for or against all resolutions. As of the Record Date, (i) there were 6,123,131 Treasury H Shares held by the Company and completed delivery (including any Treasury Shares held or deposited with CCASS) and no voting rights of such Treasury Shares have been exercised at the EGM; and (ii) except for the Treasury Shares held or deposited with CCASS, there were no Shares repurchased by the Company which are pending cancellation and should be excluded from the total number of Shares for the purpose of the EGM. According to the Circular, Dr. Jonathon Zhong Zhao and Dr. Zheng Li and their associates and parties in concert (i.e. Dr. Shengping Sam Zhong (鍾生平), Ms. Na Wei (衛娜), Zhuhai Tongqiao Investment Center (Limited Partnership)* (珠海通橋投資中心(有限合

夥)), Hangzhou Fujiang Investment Partnership (Limited Partnership)* (杭州涪江投資合夥企業(有限合夥)), Zhuhai Guichuang Investment Center (Limited Partnership)* (珠海歸創投資中心(有限合夥)) (formerly known as Zhuhai Guichuang Equity Investment Center (Limited Partnership)* (珠海歸創股權投資中心(有限合夥))), Hangzhou Guiqiao Enterprise Management Partnership (Limited Partnership)* (杭州歸橋企業管理合夥企業(有限合夥)) (formerly known as Ningbo Guiqiao Enterprise Management Partnership (Limited Partnership)* (寧波歸橋企業管理合夥企業(有限合夥))), Hangzhou Yuyihui Investment Partnership (Limited Partnership)* (杭州語意慧企業管理合夥企業(有限合夥) (formerly known as Huzhou Yuyihui Investment Partnership (Limited Partnership)* (湖州語意慧企業管理合夥企業(有限合夥))) and WEA Enterprises, LLC) who are involved in or interested in resolutions numbered 4, 5 and 6 (the "**Conditional Grants**") are required to abstain from voting in respect of the relevant resolutions. Therefore, as of the Record Date, both Dr. Zhao and Dr. Li and their associates and parties in concert, in aggregate holding 92,173,919 Shares, representing approximately 28.44% of the issued share capital of the Company (excluding the aforementioned Treasury Shares) as at the Record Date, abstained from voting in respect of the resolutions regarding the Conditional Grants. Mr. Yang Xie, holding 567,599 Shares, representing approximately 0.18% of the issued share capital of the Company (excluding Treasury Shares) as of the Record Date, abstained from voting in respect of the resolutions regarding the Conditional Grants. Ms. Hongbo Wang, as a supervisor of the Company, who directly held 71,828 H Shares, representing approximately 0.02% of the issued share capital of the Company (excluding Treasury Shares) as of the Record Date, abstained from voting in respect of the resolutions regarding Conditional Grants at the EGM. As a result, 231,245,524 H Shares (excluding Treasury Shares held or deposited with CCASS), were the total number of Shares of the Company entitling the Shareholders to attend and vote for or against the resolutions numbered 4, 5 and 6.

Save as disclosed above, to the best knowledge, information and belief of the Directors: (1) no Shareholders were required under the Listing Rules to abstain from voting on any of the resolutions at the EGM; (2) there were no Shares entitling the holders thereof to attend the EGM and abstain from voting in favor of the resolutions at the EGM under Rule 13.40 of the Listing Rules; and (3) no Shareholders have indicated in the Circular that they intend to vote against or to abstain from voting on the resolutions at the EGM. The number of Shareholders and proxies of Shareholders attending the EGM was 1, holding a total of 223,874,426 Shares (save and except for the resolutions numbered 4, 5 and 6) with voting rights (including 7,781,257 Domestic Shares and 216,093,169 H Shares), representing approximately 69.08% of the total number of Shares with voting rights; for the resolutions numbered 4, 5 and 6, the number of Shareholders and proxies of Shareholders attending the EGM held a total of 131,190,080 Shares with voting rights (all are H Shares), representing approximately 56.73% of the total number of Shares with voting rights.

Tricor Investor Services Limited, the Company's H share registrar, acted as the scrutineer for the vote-taking at the EGM. The convening of the EGM was in compliance with the Company Law of the People's Republic of China and the Articles of Association.

Mr. Yang Xie, an executive Director attended the Meetings in person; while Dr. Jonathon Zhong Zhao and Dr. Zheng Li, both being executive Directors; Dr. Steven Dasong Wang and Mr. Dongfang Li, both being non-executive Directors; and Dr. Jian Ji, Ms. Yun Qiu and Dr. Xiang Qian, all being independent non-executive Directors, attended the Meeting by electronic means.

The poll results in respect of the resolutions proposed at the EGM were as follows:

Ordinary Resolutions		Number of votes			
		For		Against	
		Number of Shares	Percentage (%)	Number of Shares	Percentage (%)
1	To consider and approve the Share Incentive Scheme;	207,607,049	92.73	16,267,377	7.27
2	To consider and approve the grant of a mandate by the Shareholders to the Board and/or the Administrative Committee to handle matters pertaining to the Share Incentive Scheme, subject to the adoption of the Share Incentive Scheme;	207,675,549	92.76	16,198,877	7.24
3	To consider and approve the service provider sublimit as defined in the Share Incentive Scheme, subject to the adoption of the Share Incentive Scheme;	205,677,049	91.87	18,197,377	8.13
4	To consider and approve the grant of 3,600,000 RSUs to Dr. Jonathon Zhong Zhao, subject to the adoption of the Share Incentive Scheme;	114,922,703	87.60	16,267,377	12.40
5	To consider and approve the grant of 1,800,000 RSUs to Mr. Yang Xie, subject to the adoption of the Share Incentive Scheme; and	114,922,703	87.60	16,267,377	12.40
6	To consider and approve the grant of 1,800,000 RSUs to Dr. Zheng Li, subject to the adoption of the Share Incentive Scheme.	114,922,703	87.60	16,267,377	12.40

As more than half of the votes from the Shareholders (including their proxies) attending the EGM were cast in favor of all the ordinary resolutions, the above resolutions were duly passed.

By order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, October 24, 2025

As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Ms. Yun Qiu and Dr. Xiang Qian as independent non-executive Directors.